News

ClearView Healthcare Partners Makes Strategic Investment in Epistemic AI

ClearView Healthcare Partners announced a $4 million strategic investment in Epistemic AI to advance next-generation biomedical AI platforms. This partnership will integrate Epistemic AI's EpistemicGPT technology across ClearView's service offerings, combining human expertise with AI capabilities to enhance operational efficiency and provide more sophisticated analysis for life sciences organizations.

Epistemic AI Unveils Next-generation Biomedical GPT Technology

Epistemic AI unveiled its breakthrough generative AI solution for life science professionals, today at the BIO International Convention. EpistemicGPT is a unique product that addresses the acute market need for immediate access to accurate and reliable biomedical information. It empowers researchers to interact with highly complex data in a way that was unimaginable until now.

Epistemic AI launches biomedical GPT at BIO

EpistemicGPT is the first proprietary multi-agent genAI technology specialized for the Life Sciences. Integrated with a curated network of billions of biomedical information sources through our Epistemic Knowledge Graph to help researchers tease out possible connections between different pieces of data.

Somnus Scientific enhances their competitive intelligence with Epistemic AI

Epistemic AI (EAI) welcomes Somnus Scientific as a new customer of its Research Intelligence Platform. Somnus Scientific develops novel micro-sensors that provide real-time measurement of propofol anesthesia and they will use the EAI platform to accelerate their competitive intelligence research and trend analysis.

AI Platform Gives CSHL Researchers Access to Vast Amounts of Data

The Cold Spring Harbor Laboratory (CSHL) has licensed an artificial intelligence platform, developed by Epistemic AI, to accelerate cystic fibrosis (CF)-related discoveries. The platform, which also contains CF-specific resources, will help the lab’s scientists to accelerate their research by providing easy access to publications and clinical trials, and connection to multiple databases.

Cold Spring Harbor Laboratory Licenses Epistemic AI Research Intelligence Platform

Epistemic AI (EAI) is pleased to announce that the Cold Spring Harbor Laboratory (CSHL) has licensed its Research Intelligence platform. With support from the Boomer Esiason Foundation (BEF), the EAI platform will help researchers at CSHL to rapidly access documents and data that provide insight into the underlying relationships among diseases, their diagnosis, treatments, and biological functions. The BEF venture philanthropy model was an instrumental component to bring this enhanced capability to CSHL.

Epistemic AI cited in important paper investigating the biological role of the glaucoma-associated glycoprotein Myocilin.

In a multi-university study of Myocilin, the authors noted that “to unveil functional relationships in the group of top-100 DEGs (top-50 up- plus top-50 down-regulated genes), we carried out a comprehensive enrichment analysis using Epistemic AI, an artificial intelligence web-based software platform”.

Raquel Atienzar-Aroca, et al. Transgenic Overexpression of Myocilin Leads to Variable Ocular Anterior Segment and Retinal Alterations Associated with Extracellular Matrix Abnormalities in Adult Zebrafish. Int J Mol Sci. 2022 Sep 1;23(17):9989.

Cincinnati Children’s Gains AI Platform to Speed CF Research

Cincinnati Children’s Hospital Medical Center will use Epistemic AI’s platform, a state-of-the-art artificial intelligence (AI) research tool for the life sciences, to augment its research into cystic fibrosis (CF) and other lung conditions. The Boomer Esiason Foundation (BEF) venture philanthropy initiative helped bring this capability to scientists at Cincinnati Children’s.

Epistemic AI launches strategic collaboration with Cincinnati Children’s Hospital Medical Center

Epistemic AI (EAI) announced that through its collaboration with the Boomer Esiason Foundation (BEF), and the leadership of Dr. Raouf Amin at Cincinnati Children’s Hospital Medical Center, that the Cincinnati Children’s Division of Pulmonary Medicine will use the EAI platform to augment and accelerate their research in Cystic Fibrosis (CF) and respiratory disease. Epistemic AI will bring AI-powered knowledge discovery to researchers and clinicians in cystic fibrosis.

Q&A with Epistemic AI: Changing the way drug discovery works

Epistemic AI has developed what it calls a Knowledge Discovery Platform which is designed to help those working within biomedical research and development. The software uses a mix of machine learning and deep learning algorithms to find existing links within biomedical knowledge, using data from multiple public and private sources.